

Massimo Franchini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1636071/publications.pdf>

Version: 2024-02-01

22
papers

437
citations

1040056

9
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

641
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. <i>Haematologica</i> , 2020, 105, 2834-2840.	3.5	114
2	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0020021.	13.6	64
3	Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 29.	4.1	35
4	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. <i>Viruses</i> , 2021, 13, 1594.	3.3	31
5	COVID-19 convalescent plasma therapy: hit fast, hit hard!. <i>Vox Sanguinis</i> , 2021, 116, 935-942.	1.5	25
6	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , 2021, 11, 1663.	2.6	19
7	The Three Pillars of COVID-19 Convalescent Plasma Therapy. <i>Life</i> , 2021, 11, 354.	2.4	17
8	Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. <i>European Journal of Haematology</i> , 2021, 107, 24-28.	2.2	16
9	How Safe Is COVID-19 Convalescent Plasma?. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2279-2281.	3.0	11
10	Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. <i>Vaccines</i> , 2022, 10, 94.	4.4	10
11	Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. <i>Reviews in Medical Virology</i> , 2022, 32, e2341.	8.3	10
12	Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review. <i>Viruses</i> , 2021, 13, 1194.	3.3	9
13	Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience. <i>Life</i> , 2022, 12, 420.	2.4	9
14	Bleeding Disorders in Primary Fibrinolysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7027.	4.1	8
15	Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. <i>Viruses</i> , 2022, 14, 1443.	3.3	7
16	Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. <i>Clinical Microbiology and Infection</i> , 2021, 27, 987-992.	6.0	6
17	High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality. <i>Transfusion</i> , 2021, 61, 1988-1990.	1.6	4
18	Convalescent plasma for COVID-19. TSUNAMI is not the final word. <i>European Journal of Internal Medicine</i> , 2022, 97, 116-118.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. <i>Journal of Clinical Medicine</i> , 2022, 11, 801.	2.4	3
20	Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?. <i>Vaccines</i> , 2022, 10, 406.	4.4	2
21	Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 915.	2.4	1
22	Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics. <i>Life</i> , 2022, 12, 614.	2.4	0